Compare EOG Resources Inc (EOG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Zoetis Inc — how do they compare? EOG Resources Inc trades at $148.79 (market cap $77.90B), while Zoetis Inc trades at $74.55 (market cap $30.20B). The key difference: EOG Resources Inc is far larger — about 2.6× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Zoetis Inc for 70 Days on average.
| EOG | ZTS | |
|---|---|---|
Market Cap | $77.90B | $30.20B |
Volume | 2,930,386 | 6,175,327 |
Sector | Energy | Health |
52-Week High | $153.74 | $147.53 |
52-Week Low | $101.78 | $69.09 |
Typical Hold Time | 59 Days | 70 Days |
Enterprise Value | $81.24B | $37.76B |
Dividend Yield | 2.75% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $149.40, up 3.6% today, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations. Valuation ratios appear attractive, including a P/E of 11.56 and EV/EBITDA of 5.84. Recent news highlights robust operational execution and disciplined capital allocation, with the company announcing a CFO transition and scheduling its Q3 2026 earnings call for November 6.
The outlook for EOG remains positive, supported by strong profitability metrics, a solid balance sheet, and a unanimous analyst buy/hold consensus with no sell ratings. Key opportunities include projected revenue growth to $26.6B in 2026 and a 5% oil volume growth target. Risks involve exposure to volatile oil prices, as seen in recent price retreats impacting energy stocks, and potential execution challenges amid macroeconomic uncertainty. The stock offers value with a consensus price target of $164.77, implying ~10% upside.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
